September 28th - October 1st, 2024
Join us at the American Academy of Otolaryngology annual meeting
Explore an opportunity to unlock the future of patient care, including COBLATION◊ Intracapsular Tonsillectomy and the Tula® Tympanstomy System.
Explore our latest technological innovations in the OTO Pavilion
Join expert leaders Dr Joshua Greene, Prof Leonel Luis, Dr Jordan Schramm and Dr Ryan Walker in this showcase educational program, featuring valuable insights on:
In-office tympanostomy with the Tula System
Get the latest clinical data, gain reimbursement guidance and hear experts share their experiences of this alternative to traditional OR-based ear tube procedures.
COBLATION Intracapsular Tonsillectomy
Participate in a compelling clinical data review and case discussion to understand how the CIT approach affects patient outcomes.
A gentler tonsillectomy
Don’t miss a chance to experience COBLATION Intracapsular Tonsillectomy (CIT). CIT involves using a COBLATION Technology wand to remove all tonsil tissue, while leaving the tonsil capsule in place.
CIT enables surgeons to reduce the likelihood of post-operative complications and pain, compared with total tonsillectomy,1 without sacrificing the efficacy of the procedure. This approach to tonsillectomy is growing in popularity.
Learn more about CIT
Ear tubes done differently
The Tula in-office Tympanostomy System provides your patients with an in-office alternative to traditional tympanostomy, utilizing revolutionary local anesthesia and a 1-click tube delivery device designed specifically to address the challenge of tube insertion in an awake child, without the use of mechanical restraints.
Learn more about the Tula System
Medical education
Disclaimers
The Tula System is intended to create a myringotomy and insert a tympanostomy tube using the Tula Tube Delivery System in paediatric (aged 6 months and older) and adult patients indicated to receive tympanostomy tubes. The Tula System is used to deliver a tympanostomy tube under local anaesthesia induced using the Tula Iontophoresis System and TYMBION, a combination of an amide local anaesthetic and an alpha and beta-adrenergic agonist. Contraindications include certain abnormal ear anatomy, sensitivity/allergy to lidocaine or other local anaesthetics, and reliance on electrically sensitive medical implants such as a pacemaker. Risks may include, but are not limited to, inadequate local anaesthesia, dizziness, and common tympanostomy procedure risks. For full prescribing information, see the Tula IFU and TYMBION Drug Package Insert at www.tulatubes.com/IFU. Rx only.
Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use.
Citattions
1. Sedgwick MJ, et al. OTO Open. 2023;7(1):e22.